-
Je něco špatně v tomto záznamu ?
Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses
K Berankova, M Szkutova, M Balikova
Jazyk angličtina Země Irsko
Grantová podpora
NR8332
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
ProQuest Central
od 1997-02-07 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 1997-02-07 do Před 2 měsíci
Health & Medicine (ProQuest)
od 1997-02-07 do Před 2 měsíci
ScienceDirect (archiv)
od 1993-01-01 do 2009-12-31
- MeSH
- 2,5-dimethoxy-4-methylamfetamin aplikace a dávkování analogy a deriváty farmakokinetika krev MeSH
- aplikace orální MeSH
- financování organizované MeSH
- halucinogeny aplikace a dávkování farmakokinetika krev MeSH
- injekce subkutánní MeSH
- játra chemie MeSH
- krysa rodu rattus MeSH
- mozek - chemie MeSH
- plíce chemie MeSH
- plynová chromatografie s hmotnostně spektrometrickou detekcí MeSH
- potkani Wistar MeSH
- soudní toxikologie MeSH
- tkáňová distribuce MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
2,5-Dimethoxy-4-bromoamphetamine (DOB) is one of the potent hallucinogenic phenylalkylamines, whose ingestion has already caused several deaths reported all over the world. However, there is insufficient information on DOB properties based on controlled pharmacokinetic studies available. The aim of this study was to clarify the distribution profile of DOB and its phenolic metabolite 2-methoxy-5-hydroxy-4-bromoamphetamine (2M5H4BA) in blood and biological tissues of experimental rats. The rats were administered a 20 mg/kg dose of DOB.HCl by oral ingestion or subcutaneous injection. Plasma and brain, liver and lung tissues were collected at 0.5, 1, 2, 4, 8, 16, and 32 h after dosing (three animals per time point). The samples were prepared by a liquid-liquid extraction procedure and the extracts were assayed by GC-MS. After per oral application, DOB peak plasma level of 320 ng/mL was reached after one-hour post dosing as well as 2M5H4BA peak concentration of 203 ng/mL. A rapid phase of DOB absorption, 2M5H4BA formation and their tissue distribution during the first two hours after application were followed by a slow decrease rate of the elimination process until 32 h. After subcutaneous application, high plasma levels of the unchanged parent drug and relatively reduced formation of its metabolite 2M5H4BA were observed. DOB maximum plasma concentration of 1143 ng/mL was reached after one-hour post application, whereas its metabolite peak level after 8 h was 213 ng/mL. The concentration profiles of both compounds in plasma after per oral and subcutaneous administration revealed the existence of significant first pass effect after per oral administration that significantly affected DOB bioavailability. DOB tissue concentrations exceeded plasma and the highest values were found in the lungs, where drug accumulation occurred with prolonged retention till 32 h after subcutaneous dose. Although the plasma/tissue transfer was more effective for the lipophilic parent drug than for its hydroxylated metabolite 2M5H4BA, the metabolite tissue levels were significant. The hallucinogenic potential of 2M5H4BA appearing in brain remains unclear as nothing is known about its pharmacological activity at present.
- 000
- 04054naa 2200457 a 4500
- 001
- bmc10011886
- 003
- CZ-PrNML
- 005
- 20131014145807.0
- 008
- 100517s2007 ie e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Beránková, Kateřina. $7 _AN040693
- 245 10
- $a Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses / $c K Berankova, M Szkutova, M Balikova
- 314 __
- $a Institute of Forensic Medicine and Toxicology, 1st Medical Faculty, Charles University in Prague, Prague, Czech Republic.
- 520 9_
- $a 2,5-Dimethoxy-4-bromoamphetamine (DOB) is one of the potent hallucinogenic phenylalkylamines, whose ingestion has already caused several deaths reported all over the world. However, there is insufficient information on DOB properties based on controlled pharmacokinetic studies available. The aim of this study was to clarify the distribution profile of DOB and its phenolic metabolite 2-methoxy-5-hydroxy-4-bromoamphetamine (2M5H4BA) in blood and biological tissues of experimental rats. The rats were administered a 20 mg/kg dose of DOB.HCl by oral ingestion or subcutaneous injection. Plasma and brain, liver and lung tissues were collected at 0.5, 1, 2, 4, 8, 16, and 32 h after dosing (three animals per time point). The samples were prepared by a liquid-liquid extraction procedure and the extracts were assayed by GC-MS. After per oral application, DOB peak plasma level of 320 ng/mL was reached after one-hour post dosing as well as 2M5H4BA peak concentration of 203 ng/mL. A rapid phase of DOB absorption, 2M5H4BA formation and their tissue distribution during the first two hours after application were followed by a slow decrease rate of the elimination process until 32 h. After subcutaneous application, high plasma levels of the unchanged parent drug and relatively reduced formation of its metabolite 2M5H4BA were observed. DOB maximum plasma concentration of 1143 ng/mL was reached after one-hour post application, whereas its metabolite peak level after 8 h was 213 ng/mL. The concentration profiles of both compounds in plasma after per oral and subcutaneous administration revealed the existence of significant first pass effect after per oral administration that significantly affected DOB bioavailability. DOB tissue concentrations exceeded plasma and the highest values were found in the lungs, where drug accumulation occurred with prolonged retention till 32 h after subcutaneous dose. Although the plasma/tissue transfer was more effective for the lipophilic parent drug than for its hydroxylated metabolite 2M5H4BA, the metabolite tissue levels were significant. The hallucinogenic potential of 2M5H4BA appearing in brain remains unclear as nothing is known about its pharmacological activity at present.
- 650 _2
- $a 2,5-dimethoxy-4-methylamfetamin $x aplikace a dávkování $7 D004290
- 650 _2
- $a 2,5-dimethoxy-4-methylamfetamin $x analogy a deriváty $x farmakokinetika $x krev $7 D004290
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a mozek - chemie $7 D001923
- 650 _2
- $a soudní toxikologie $7 D053593
- 650 _2
- $a plynová chromatografie s hmotnostně spektrometrickou detekcí $7 D008401
- 650 _2
- $a halucinogeny $x aplikace a dávkování $x farmakokinetika $x krev $7 D006213
- 650 _2
- $a injekce subkutánní $7 D007279
- 650 _2
- $a játra $x chemie $7 D008099
- 650 _2
- $a plíce $x chemie $7 D008168
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a tkáňová distribuce $7 D014018
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Rohanová, Miroslava $7 xx0146000
- 700 1_
- $a Balíková, Marie, $d 1945- $7 jn99240000049
- 773 0_
- $t Forensic Science International $w MED00001844 $g Roč. 170, č. 2-3 (2007), s. 94-99 $x 0379-0738
- 910 __
- $a ABA008 $b x $y 8 $z 0
- 990 __
- $a 20100525162035 $b ABA008
- 991 __
- $a 20131014150334 $b ABA008
- 999 __
- $a ok $b bmc $g 725744 $s 588896
- BAS __
- $a 3
- BMC __
- $a 2007 $b 170 $c 2-3 $d 94-99 $m Forensic science international $n Forensic Sci Int $x MED00001844 $i 0379-0738
- GRA __
- $a NR8332 $p MZ0
- LZP __
- $a 2010-B2/dkme